Nagoya University AI spinout PulmoGate raises $3.3M seed round
What's the deal? PulmoGate, a Nagoya University medical AI spinout, has raised about US$2.54M in a seed round led by Beyond Next VenturesDealroom has a profile for this one. Try Dealroom →. Teijin PharmaDealroom has a profile for this one. Try Dealroom →, MUFG Capital, and a STATION AiDealroom has a profile for this one. Try Dealroom →/DeepcoreDealroom has a profile for this one. Try Dealroom →-run fund also joined through a third-party share allotment.
What's the endgame? The startup targets interstitial lung disease (ILD), where accurate diagnosis typically requires several specialists reviewing a case together — a setup few hospitals can staff in-house. PulmoGate builds on Nagoya University research to offer remote multidisciplinary review supporting online second opinions. It is also developing diagnostic AI, treatment-planning AI, and home monitoring tools, all still in research and development and not approved as medical devices.
Why now? ILD prevalence in Japan roughly doubled between 2015 and 2023, rising to 1,301 per 100,000, and it ranks as the country's 11th leading cause of death. The overall five-year survival rate is 59.9%, falling to 32.1% for idiopathic pulmonary fibrosis, its main subtype.
The funding will expand the network of institutions offering ILD online second opinions and advance research, clinical evaluation, and regulatory work for its AI tools.
Who's behind it? Chief executive officer Tomo Tominaga previously built a preventive healthcare business to more than 4,700 participating institutions before selling it to Medipal Holdings in 2024. Co-founder and chief medical officer Daiki Furukawa, a physician at Nagoya University Hospital, leads the underlying ILD research.
The signal: The round stands out less for its size than for its backers — a pharma company, a bank-affiliated fund, and specialist investors lining up behind a clinically grounded idea. The test now is whether PulmoGate can validate its service and carve a route into routine care.
Read more: prtimes.jp
Image credit: Generated with Gemini